Related Experiment Video

Updated: Jul 5, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

STAT4 but not TRAF1/C5 variants influence the risk of developing rheumatoid arthritis and systemic lupus

R J Palomino-Morales1, A Rojas-Villarraga, C I González

  • 1Instituto de Biomedicina López-Neyra, Consejo Superior de Investigaciones Científicas, Granada, Spain.

Genes and Immunity
|April 25, 2008
PubMed

Insights

The STAT4 rs7574865 gene variant increases the risk for rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). TRAF1/C5 gene polymorphisms did not show an association with these autoimmune diseases in Colombians.

Area of Science:

  • Genetics
  • Immunology
  • Rheumatology

Background:

  • Rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) are complex autoimmune diseases with shared genetic risk factors.
  • Identifying specific gene polymorphisms associated with RA and SLE is crucial for understanding disease pathogenesis and susceptibility.

Purpose of the Study:

  • To investigate the association between STAT4 (rs7574865) and TRAF1/C5 (rs10818488, rs2900180) gene polymorphisms and the risk of developing RA and SLE.
  • To evaluate the role of these polymorphisms in a Colombian population.

Main Methods:

  • A case-control study was conducted with 839 participants, including patients with RA (N=274), SLE (N=144), and healthy controls (N=421).
  • Genotyping was performed using a polymerase chain reaction system with a TaqMan allelic discrimination assay.

Main Results:

  • The STAT4 rs7574865T allele was significantly associated with an increased risk of developing SLE (P=0.0005; OR 1.62) and RA (P=0.008; OR 1.36).
  • No significant association was found between the examined TRAF1/C5 polymorphisms and the risk of RA or SLE.

Conclusions:

  • The STAT4 rs7574865 polymorphism is a susceptibility factor for both RA and SLE in the Colombian population.
  • These findings support the hypothesis of a common genetic origin for autoimmune diseases and highlight STAT4 as a key player.

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...